Relapse-free cure from multidrug-resistant tuberculosis in Germany

Multidrug-resistant (MDR) tuberculosis (TB), defined by bacillary resistance against rifampicin and isoniazid, has been identified as a global threat to mankind [1]. According to the latest report by the European Centres for Disease Prevention and Control, and World Health Organization (WHO) regiona...

Full description

Saved in:
Bibliographic Details
Published inThe European respiratory journal Vol. 51; no. 2; p. 1702122
Main Authors Heyckendorf, Jan, van Leth, Frank, Kalsdorf, Barbara, Olaru, Ioana D, Günther, Gunar, Salzer, Helmut J F, Terhalle, Elena, Rolling, Thierry, Glattki, Georg, Müller, Marius, Schuhmann, Maren, Avsar, Korkut, Lange, Christoph
Format Journal Article
LanguageEnglish
Published England European Respiratory Society Journals Ltd 01.02.2018
Subjects
Clinical outcomes
Isoniazid
Medicin och hälsovetenskap
Multidrug resistance
Multidrug resistant organisms
Rifampin
Tuberculosis
Europe
Online AccessGet full text

Cover

More Information
Summary:Multidrug-resistant (MDR) tuberculosis (TB), defined by bacillary resistance against rifampicin and isoniazid, has been identified as a global threat to mankind [1]. According to the latest report by the European Centres for Disease Prevention and Control, and World Health Organization (WHO) regional office for Europe, only approximately 50% of MDR-TB patients in Europe reach favourable treatment outcomes [2]. Successful treatment outcomes are achieved for less than 25% of patients with extensively drug-resistant (XDR)-TB (MDR plus resistance against a least one fluoroquinolone and one second-line injectable drug) in the European Union/European Economic Area Countries [2].
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ObjectType-Undefined-3
ISSN:0903-1936
1399-3003
1399-3003
DOI:10.1183/13993003.02122-2017